Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

Core Viewpoint - Tiziana Life Sciences is celebrating a significant milestone by ringing the Nasdaq Closing Bell, highlighting its advancements in immunomodulation therapies, particularly its lead candidate, intranasal foralumab, which targets neurodegenerative and inflammatory diseases [1][2][3]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using transformational drug delivery technologies, specifically intranasal delivery methods [6]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in patients [5][6]. Product Development - Intranasal foralumab aims to improve efficacy, safety, and tolerability compared to traditional intravenous methods, targeting diseases such as multiple sclerosis, Alzheimer's disease, and ALS [2][6]. - The company has recently achieved significant milestones, including the dosing of the first patient in its Phase 2 Alzheimer's trial and expansions in other key studies [3][4]. Clinical Trials - Foralumab has been administered to 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) in an open-label program, with all patients showing either improvement or stability of disease within six months [4]. - The drug is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled trial for non-active secondary progressive multiple sclerosis [4].